Cardiovascular Systems Company Profile (NASDAQ:CSII)

About Cardiovascular Systems

Cardiovascular Systems logoCardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Exchange: NASDAQ
  • Symbol: CSII
  • CUSIP: 14161910
Key Metrics:
  • Previous Close: $27.81
  • 50 Day Moving Average: $26.06
  • 200 Day Moving Average: $24.63
  • 52-Week Range: $8.19 - $29.70
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 347.63
  • P/E Growth: -20.47
  • Market Cap: $906.66M
  • Outstanding Shares: 32,602,000
  • Beta: 2.34
  • Net Margins: -14.74%
  • Return on Equity: -15.34%
  • Return on Assets: -10.96%
  • Current Ratio: 3.80%
  • Quick Ratio: 3.30%
Additional Links:
Companies Related to Cardiovascular Systems:

Analyst Ratings

Consensus Ratings for Cardiovascular Systems (NASDAQ:CSII) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $33.40 (20.10% upside)

Analysts' Ratings History for Cardiovascular Systems (NASDAQ:CSII)
DateFirmActionRatingPrice TargetDetails
1/30/2017Lake Street CapitalInitiated CoverageBuy$40.00View Rating Details
1/26/2017Needham & Company LLCBoost Price TargetBuy$27.00 -> $32.00View Rating Details
11/15/2016Leerink SwannReiterated RatingOutperform$30.00View Rating Details
10/27/2016Feltl & Co.UpgradeBuy -> Strong-Buy$30.00View Rating Details
10/7/2016JMP SecuritiesInitiated CoverageOutperform$35.00View Rating Details
8/4/2016Bank of America CorpUpgradeUnderperform -> NeutralView Rating Details
12/23/2015Northcoast ResearchInitiated CoverageBuy$18.00View Rating Details
10/8/2015William BlairReiterated RatingOutperformView Rating Details
10/8/2015Dougherty & CoLower Price TargetBuy$50.00 -> $32.00View Rating Details
10/8/2015Benchmark Co.Lower Price TargetBuy$49.00 -> $20.00View Rating Details
(Data available from 2/25/2015 forward)


Earnings History for Cardiovascular Systems (NASDAQ:CSII)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2017Q217($0.06)$0.03$49.72 million$50.00 millionViewN/AView Earnings Details
10/26/2016Q117($0.19)($0.06)$205.50 million$49.80 millionViewListenView Earnings Details
8/3/2016Q416($0.20)($0.15)$46.01 million$48.50 millionViewN/AView Earnings Details
5/4/2016Q316($0.54)($0.31)$42.13 million$44.50 millionViewN/AView Earnings Details
1/21/2016Q216($0.50)($0.47)$44.82 million$41.40 millionViewListenView Earnings Details
11/4/2015Q116($0.42)($0.41)$43.90 million$43.90 millionViewN/AView Earnings Details
8/5/2015Q415($0.30)($0.27)$50.10 million$48.50 millionViewN/AView Earnings Details
4/29/2015Q315($0.34)($0.34)$46.84 million$47.00 millionViewListenView Earnings Details
1/28/2015Q215($0.35)($0.17)$43.97 million$44.70 millionViewListenView Earnings Details
10/29/2014Q115($0.33)($0.26)$40.24 million$41.40 millionViewListenView Earnings Details
8/6/2014Q214($0.28)($0.31)$37.21 million$39.56 millionViewListenView Earnings Details
4/30/2014Q114($0.32)($0.32)$34.15 million$34.90 millionViewListenView Earnings Details
1/29/2014Q2($0.34)($0.32)$30.62 million$32.30 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.30)($0.28)$27.18 million$28.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cardiovascular Systems (NASDAQ:CSII)
Current Year EPS Consensus Estimate: $-0.09 EPS
Next Year EPS Consensus Estimate: $0.08 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($0.61)($0.27)($0.44)
Q2 20164($0.50)($0.23)($0.40)
Q3 20165($0.51)($0.33)($0.41)
Q4 20165($0.47)($0.20)($0.34)
Q1 20174($0.44)($0.14)($0.26)
Q2 20174($0.26)($0.05)($0.11)
Q3 20174($0.05)($0.02)($0.04)
Q4 20174($0.05)($0.01)($0.03)
Q1 20183$0.00$0.02$0.01
Q2 20184$0.02$0.03$0.03
Q3 20183$0.02$0.05$0.04
Q4 20184$0.04$0.09$0.07
(Data provided by Zacks Investment Research)


Dividend History for Cardiovascular Systems (NASDAQ:CSII)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Cardiovascular Systems (NASDAQ:CSII)
Insider Ownership Percentage: 3.60%
Institutional Ownership Percentage: 72.30%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/18/2016Alexander RosensteinGeneral CounselSell529$26.80$14,177.20View SEC Filing  
11/18/2016Edward M BrownDirectorSell10,000$26.78$267,800.00View SEC Filing  
11/18/2016Laura GillundInsiderSell1,268$26.79$33,969.72View SEC Filing  
11/15/2016Edward M BrownDirectorSell10,000$24.95$249,500.00View SEC Filing  
10/10/2016Paul A KoehnSVPSell30,910$25.07$774,913.70View SEC Filing  
9/20/2016Camber Capital Management LlcMajor ShareholderSell1,100,000$23.26$25,586,000.00View SEC Filing  
9/7/2016Paul A KoehnSVPSell5,969$25.02$149,344.38View SEC Filing  
8/22/2016Alexander RosensteinGeneral CounselSell234$23.82$5,573.88View SEC Filing  
8/22/2016Kevin J KennyCOOSell3,166$23.95$75,825.70View SEC Filing  
8/22/2016Laura GillundInsiderSell1,395$23.93$33,382.35View SEC Filing  
8/22/2016Laurence L BetterleyCFOSell3,568$23.96$85,489.28View SEC Filing  
8/22/2016Paul A KoehnSVPSell2,527$23.92$60,445.84View SEC Filing  
8/17/2016Paul A KoehnSVPSell4,000$22.17$88,680.00View SEC Filing  
2/26/2016Paul A KoehnSVPSell956$38.79$37,083.24View SEC Filing  
2/23/2016Camber Capital Management LlcMajor ShareholderBuy250,000$7.55$1,887,500.00View SEC Filing  
1/25/2016Scott R WardCEOBuy2,700$9.30$25,110.00View SEC Filing  
10/2/2015Robert J. ThatcherinsiderSell64,700$16.31$1,055,257.00View SEC Filing  
9/2/2015David MartinCEOSell19,646$23.81$467,771.26View SEC Filing  
9/1/2015Kevin J KennyCOOSell5,289$23.85$126,142.65View SEC Filing  
9/1/2015Laurence L BetterleyCFOSell9,597$23.96$229,944.12View SEC Filing  
9/1/2015Paul A KoehnSVPSell4,946$23.86$118,011.56View SEC Filing  
9/1/2015Robert J ThatcherInsiderSell5,282$23.85$125,975.70View SEC Filing  
8/18/2015David MartinCEOSell17,688$23.99$424,335.12View SEC Filing  
8/18/2015Kevin J. KennyCOOSell3,913$24.00$93,912.00View SEC Filing  
8/18/2015Laurence L BetterleyCFOSell8,476$24.00$203,424.00View SEC Filing  
8/18/2015Paul A. KoehnSVPSell4,402$23.99$105,603.98View SEC Filing  
8/18/2015Robert J. ThatcherinsiderSell2,960$23.99$71,010.40View SEC Filing  
8/12/2015Brent G BlackeyDirectorBuy2,500$22.74$56,850.00View SEC Filing  
5/28/2015Paul A KoehnSVPSell4,389$27.86$122,277.54View SEC Filing  
5/1/2015Brent G BlackeyDirectorBuy2,500$29.38$73,450.00View SEC Filing  
2/10/2015David MartinCEOSell7,500$35.85$268,875.00View SEC Filing  
2/5/2015David MartinCEOSell4,500$34.96$157,320.00View SEC Filing  
1/29/2015Kevin J KennyVPSell4,212$35.00$147,420.00View SEC Filing  
9/3/2014David MartinCEOSell10,248$28.85$295,654.80View SEC Filing  
9/3/2014Kevin J KennyVPSell3,528$28.85$101,782.80View SEC Filing  
9/3/2014Laurence L BetterleyCFOSell4,674$28.82$134,704.68View SEC Filing  
9/3/2014Paul A KoehnSVPSell2,612$28.85$75,356.20View SEC Filing  
9/3/2014Robert J ThatcherInsiderSell2,791$28.85$80,520.35View SEC Filing  
8/28/2014Paul A KoehnSVPSell1,315$28.82$37,898.30View SEC Filing  
8/22/2014David MartinCEOSell13,957$29.03$405,171.71View SEC Filing  
8/22/2014Kevin J KennyVPSell2,914$29.09$84,768.26View SEC Filing  
8/22/2014Laurence L BetterleyCFOSell6,578$29.02$190,893.56View SEC Filing  
8/22/2014Paul A KoehnSVPSell2,755$29.06$80,060.30View SEC Filing  
8/22/2014Robert J ThatcherInsiderSell3,225$29.06$93,718.50View SEC Filing  
8/19/2014David MartinCEOSell11,754$29.28$344,157.12View SEC Filing  
8/19/2014Kevin J KennyVPSell2,117$29.28$61,985.76View SEC Filing  
8/19/2014Laurence L BetterleyCFOSell5,725$29.28$167,628.00View SEC Filing  
8/19/2014Paul A KoehnSVPSell2,168$29.28$63,479.04View SEC Filing  
8/19/2014Robert J ThatcherInsiderSell2,537$29.28$74,283.36View SEC Filing  
7/16/2014David MartinCEOSell10,703$28.83$308,567.49View SEC Filing  
7/16/2014Kevin J KennyVPSell3,007$28.83$86,691.81View SEC Filing  
7/16/2014Laurence L BetterleyCFOSell3,984$28.83$114,858.72View SEC Filing  
7/16/2014Paul A KoehnSVPSell2,716$28.83$78,302.28View SEC Filing  
7/16/2014Robert J ThatcherInsiderSell2,939$28.83$84,731.37View SEC Filing  
4/25/2014Kevin KennyVPSell15,484$28.79$445,784.36View SEC Filing  
2/24/2014David MartinCEOSell29,200$37.31$1,089,452.00View SEC Filing  
2/20/2014Kevin KennyVPSell6,779$36.02$244,179.58View SEC Filing  
1/30/2014David MartinCEOSell50,000$35.12$1,756,000.00View SEC Filing  
1/30/2014Robert ThatcherVPSell35,139$35.06$1,231,973.34View SEC Filing  
11/22/2013Robert ThatcherVPSell22,384$32.82$734,642.88View SEC Filing  
10/31/2013James E FlahertyInsiderSell34,819$30.35$1,056,756.65View SEC Filing  
10/23/2013David MartinCEOSell154,080$27.73$4,272,638.40View SEC Filing  
10/23/2013James E FlahertyInsiderSell36,682$26.85$984,911.70View SEC Filing  
10/23/2013Robert J ThatcherVPSell23,426$28.19$660,378.94View SEC Filing  
10/22/2013Kevin J KennyVPSell5,608$27.31$153,154.48View SEC Filing  
10/16/2013Kevin J KennyVPSell4,182$22.95$95,976.90View SEC Filing  
10/14/2013David MartinCEOSell21,170$22.00$465,740.00View SEC Filing  
9/20/2013David MartinCEOSell6,702$20.24$135,648.48View SEC Filing  
9/20/2013James FlahertyInsiderSell2,066$20.28$41,898.48View SEC Filing  
9/20/2013Robert ThatcherVPSell1,274$20.28$25,836.72View SEC Filing  
9/19/2013Laurence BetterleyCFOSell2,694$20.32$54,742.08View SEC Filing  
9/19/2013Paul KoehnSVPSell1,094$20.32$22,230.08View SEC Filing  
9/18/2013David MartinCEOSell8,030$20.94$168,148.20View SEC Filing  
9/18/2013James FlahertyInsiderSell2,970$20.94$62,191.80View SEC Filing  
9/18/2013Laurence BetterleyCFOSell4,324$20.93$90,501.32View SEC Filing  
9/18/2013Paul KoehnSVPSell1,732$20.93$36,250.76View SEC Filing  
9/18/2013Robert ThatcherVPSell1,731$20.94$36,247.14View SEC Filing  
9/10/2013John FriedmanDirectorSell48,273$20.73$1,000,699.29View SEC Filing  
8/30/2013David MartinCEOSell21,552$20.64$444,833.28View SEC Filing  
8/30/2013James FlahertyInsiderSell7,165$20.64$147,885.60View SEC Filing  
8/30/2013Kevin KennyVPSell1,899$20.64$39,195.36View SEC Filing  
8/30/2013Laurence BetterleyCFOSell8,692$20.64$179,402.88View SEC Filing  
8/27/2013David MartinCEOSell27,229$21.07$573,715.03View SEC Filing  
8/27/2013James FlahertyInsiderSell9,051$21.07$190,704.57View SEC Filing  
8/27/2013Kevin KennyVPSell2,396$21.07$50,483.72View SEC Filing  
8/27/2013Laurence BetterleyCFOSell10,982$21.07$231,390.74View SEC Filing  
8/16/2013James FlahertyInsiderSell1,255$20.51$25,740.05View SEC Filing  
8/16/2013Laurence BetterleyCFOSell1,568$20.51$32,159.68View SEC Filing  
8/14/2013James FlahertyInsiderSell4,902$21.31$104,461.62View SEC Filing  
8/13/2013Kevin KennyVPSell2,529$21.20$53,614.80View SEC Filing  
8/8/2013James FlahertyInsiderSell19,649$22.27$437,583.23View SEC Filing  
7/30/2013David MartinCEOSell11,094$19.69$218,440.86View SEC Filing  
7/30/2013Laurence L BetterleyCFOSell6,579$19.72$129,737.88View SEC Filing  
7/30/2013Robert J ThatcherVPSell3,112$19.86$61,804.32View SEC Filing  
6/3/2013James E FlahertyInsiderSell10,000$21.00$210,000.00View SEC Filing  
5/31/2013Paul A KoehnVPSell2,472$20.00$49,440.00View SEC Filing  
5/28/2013Kevin J KennyVPSell4,182$19.95$83,430.90View SEC Filing  
5/20/2013Glen D NelsonDirectorBuy10,250$18.47$189,317.50View SEC Filing  
5/16/2013Glen D NelsonDirectorBuy4,753$18.93$89,974.29View SEC Filing  
5/13/2013Glen D NelsonDirectorBuy18,393$18.11$333,097.23View SEC Filing  
11/13/2012Glen D NelsonDirectorBuy33,000$11.96$394,680.00View SEC Filing  
8/23/2012David MartinCEOSell10,510$9.07$95,325.70View SEC Filing  
8/23/2012James E FlahertyInsiderSell4,018$9.07$36,443.26View SEC Filing  
8/23/2012Laurence L BetterleyCFOSell4,770$9.07$43,263.90View SEC Filing  
8/23/2012Paul A KoehnVPSell2,496$9.07$22,638.72View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Cardiovascular Systems (NASDAQ:CSII)
DateHeadline logoCardiovascular Systems, Inc. (NASDAQ:CSII) Files An 8-K Departure of Directors or Certain Officers; Election of ... - Market Exclusive (NASDAQ:CSII) - February 23 at 9:31 PM logoHenry Schein Inks Agreement for Rijuven's CardioSleeve (NASDAQ:CSII) - February 23 at 4:31 PM logo4:40 am Cardiovascular Systems reports 1-year results of COAST IDE Study in Late-Breaking (NASDAQ:CSII) - February 22 at 9:37 AM logoCARDIOVASCULAR SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex (NASDAQ:CSII) - February 22 at 9:37 AM logoCardiovascular : Releases 1-Year Results from COAST IDE Study in Late-Breaking Presentation at 2017 Cardiovascular Research Technologies Conference (NASDAQ:CSII) - February 21 at 5:18 PM logoCardiovascular Systems Releases 1-Year Results from COAST IDE Study in Late-Breaking Presentation at … (NASDAQ:CSII) - February 21 at 5:18 PM logoCardiovascular Systems Releases 1-Year Results from COAST IDE Study in Late-Breaking Presentation at 2017 Cardiovascular Research Technologies Conference (NASDAQ:CSII) - February 21 at 5:18 PM logoHenry Schein to Acquire SAS to Strengthen Dental Offerings (NASDAQ:CSII) - February 21 at 5:18 PM logoMedtronic (MDT) Beats on Q3 Earnings, Retains Sales View (NASDAQ:CSII) - February 21 at 5:18 PM logoEcolab's (ECL) Earnings, Revenues Miss Estimates in Q4 (NASDAQ:CSII) - February 21 at 5:18 PM logoHenry Schein (HSIC) Tops Q4 Earnings, Reaffirms '17 View (NASDAQ:CSII) - February 21 at 5:18 PM logoCardiovascular Systems Announces Healthcare Veteran Martha Goldberg Aronson Joins Board of Directors (NASDAQ:CSII) - February 21 at 5:18 PM
News IconCardiovascular Systems Inc CSII Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:CSII) - February 20 at 11:41 AM logoGenomic Health (GHDX) Earnings Surpass Estimates in Q4 (NASDAQ:CSII) - February 16 at 12:28 PM logoOmnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss (NASDAQ:CSII) - February 16 at 12:28 PM logoChemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View (NASDAQ:CSII) - February 16 at 12:28 PM logoLabCorp (LH) Q4 Earnings and Revenues Beat, Offers View (NASDAQ:CSII) - February 16 at 12:28 PM
News IconFanning the Flames: Increased Volatility Noted on Shares of Cardiovascular Systems, Inc. (NASDAQ:CSII) - Aiken Advocate (NASDAQ:CSII) - February 14 at 5:24 PM
News IconInstitutional Ownership Update on Cardiovascular Systems, Inc. (NASDAQ:CSII) - Rockville Register (NASDAQ:CSII) - February 14 at 5:24 PM logoMedtronic (MDT) Adds New Tools, Expands Coronary Suite (NASDAQ:CSII) - February 14 at 5:24 PM logoETFs with exposure to Cardiovascular Systems, Inc. : February 14, 2017 (NASDAQ:CSII) - February 14 at 5:24 PM logoNuVasive (NUVA) Beats Q4 Earnings, Revenues; Guides 2017 (NASDAQ:CSII) - February 10 at 4:52 PM logoNuVasive (NUVA) Beats Q4 Earnings, Revenues; Guides 2017 (NASDAQ:CSII) - February 10 at 4:52 PM logoCardiovascular Systems to Present at LEERINK Partners 6th Annual ... - Business Wire (press release) (NASDAQ:CSII) - February 9 at 5:00 PM
News IconLevels in Review on Shares of Cardiovascular Systems, Inc. (NASDAQ:CSII) - Sherwood Daily (NASDAQ:CSII) - February 9 at 5:00 PM logoCardiovascular Systems to Present at LEERINK Partners 6th Annual Global Healthcare Conference (NASDAQ:CSII) - February 9 at 5:00 PM logoCVS Health (CVS) Beats on Q4 Earnings, Retains '17 View (NASDAQ:CSII) - February 9 at 5:00 PM logoZimmer Biomet (ZBH) Launches Subchondroplasty Procedure (NASDAQ:CSII) - February 9 at 5:00 PM logoMyriad Genetics (MYGN): Q2 Impressive, 2017 View a Drag (NASDAQ:CSII) - February 9 at 5:00 PM logoCARDIOVASCULAR SYSTEMS INC Financials (NASDAQ:CSII) - February 9 at 5:00 PM logoMyriad Genetics (MYGN) Beats on Q2 Earnings, Narrows View (NASDAQ:CSII) - February 8 at 4:58 PM logoLandmark Study from Cardiovascular Systems Demonstrates Sustained Benefit of Endovascular Intervention in ... - Business Wire (press release) (NASDAQ:CSII) - February 7 at 10:38 PM logoCardiovascular Systems, Inc. :CSII-US: Earnings Analysis: Q2, 2017 By the Numbers : February 7, 2017 (NASDAQ:CSII) - February 7 at 5:37 PM logoLandmark Study from Cardiovascular Systems Demonstrates Sustained Benefit of Endovascular Intervention in Patients with Lower Extremity Peripheral Artery Disease (NASDAQ:CSII) - February 6 at 9:39 PM logo6:03 pm Cardiovascular Systems presented landmark study from cardiovascular systems that demonstrates sustained benefit of endovascular intervention in patients with lower extremity peripheral artery disease (NASDAQ:CSII) - February 6 at 9:39 PM logoCardiovascular : Reports Fiscal 2017 Second-Quarter Financial Results (NASDAQ:CSII) - February 2 at 10:00 PM logoEdwards Lifesciences (EW) Beats on Earnings & Sales in Q4 (NASDAQ:CSII) - February 2 at 4:57 PM logoHologic (HOLX) Beats on Q1 Earnings, Lowers '17 Guidance (NASDAQ:CSII) - February 2 at 4:57 PM logoIDEXX Laboratories (IDXX) Q4 Earnings Rise; Tweaks View (NASDAQ:CSII) - February 2 at 4:57 PM logoIllumina (ILMN) Beats Q4 Earnings & Revenues, Guides 2017 (NASDAQ:CSII) - February 1 at 4:52 PM logoThermo Fisher (TMO) Q4 Earnings Beat, Organic Sales Flat (NASDAQ:CSII) - January 31 at 5:03 PM logoHill-Rom TruSystem 3000 Table Boosts Surgical Solution Suite (NASDAQ:CSII) - January 31 at 5:03 PM logoZimmer Biomet (ZBH) Beats on Q4 Earnings, Knees Improve (NASDAQ:CSII) - January 31 at 5:03 PM
News IconTime to Buy Cardiovascular Systems Inc (CSII) After The Completion of This Bullish Wedge Up? (NASDAQ:CSII) - January 30 at 10:26 PM
News IconSignal Watch: Checking the Numbers for Cardiovascular Systems Inc. (CSII) - Market Point (NASDAQ:CSII) - January 30 at 5:25 PM
News IconCardiovascular Systems Inc (CSII) is Initiated by Lake Street to "Buy" - Highland Mirror (NASDAQ:CSII) - January 30 at 5:25 PM logoCoverage initiated on Cardiovascular Systems by Lake Street (NASDAQ:CSII) - January 30 at 5:25 PM
News IconEarnings Take Center Stage; Analysts Weighing in on Cardiovascular Systems, Inc. (NASDAQ:CSII) - Aiken Advocate (NASDAQ:CSII) - January 27 at 6:00 PM logoCardiovascular Systems (CSII) Q2 Earnings Better Estimates (NASDAQ:CSII) - January 27 at 6:00 PM
News IconStock Focus: Watching RSI Levels on Shares of Cardiovascular Systems Inc. (CSII) - Market Point (NASDAQ:CSII) - January 26 at 10:45 PM


What is Cardiovascular Systems' stock symbol?

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Where is Cardiovascular Systems' stock going? Where will Cardiovascular Systems' stock price be in 2017?

6 analysts have issued 12 month price objectives for Cardiovascular Systems' shares. Their forecasts range from $30.00 to $40.00. On average, they expect Cardiovascular Systems' share price to reach $33.40 in the next year.

When will Cardiovascular Systems announce their earnings?

Cardiovascular Systems is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.

What are analysts saying about Cardiovascular Systems stock?

Here are some recent quotes from research analysts about Cardiovascular Systems stock:

  • Needham & Company LLC analysts commented, "CSII's F2Q17 revenue and EPS beat consensus. However, F3Q17 revenue and EPS guidance was slightly below consensus. CSII continued on its path to profitability with adjusted EBITDA of $4.6M and cash flow of $5.9M (excluding a one-time $10M payment from Medikit). While revenue growth exceeded 20% Y/ Y for the first time in six quarters, we note that F2Q17 marked the bottom for its revenue growth comps. And although CSII's revenue growth may slow as it faces increasingly difficult comps over the next few quarters, we think it can sustain doubledigit revenue growth. We think that F3Q17 guidance is conservative, and we expect additional revenue and EBITDA upside. Reiterate Buy rating." (1/26/2017)
  • According to Zacks Investment Research, "In the last six months, Cardiovascular Systems has steadily outperformed the broader medical product market trend with respect to price performance. Recently, the company posted solid first-quarter fiscal 2016 performance which further improved the trend. We are encouraged by the company’s improving operating expense scenario which was the main factor for the year-over-year improvement in the loss figure. Cardiovascular Systems stands to gain from several favorable trends in the peripheral artery diseases as well coronary artery disease markets. Moreover, management is optimistic about engineering enhancements and higher production volumes which may continue to reduce unit cost in the quarters ahead. Besides, the completion of a settlement agreement with the Department of Justice is an upside. On the flip side, the company operates in the competitive medical device industry, which gets significantly affected by new product introductions." (1/17/2017)

  • Leerink Swann analysts commented, "We view this quarterly performance as certainly positive and encouraging, again perhaps suggesting that the business — notably the salesforce — has stabilized, execution has improved, and CSII is back on an accelerating sales growth trajectory. But given the recent history of sales force disruptions, we’re inclined to wait for another quarter to see tangible benefits and further proof that the salesforce stabilization is sustainable — as well as the naming of a new permanent CEO — before leaving the sidelines. Workforce Reduction Likely More Back-Office Related. In F3Q16, CSII will take a $4.5M one-time restructuring charge tied to the 8% workforce reductions. We checked with the company last night, and while details were sparse, it appears the cuts are broad-based across the organization and efforts were already underway to implement these workforce reductions in the most recent quarter. But with the recent efforts to stabilize the salesforce, we’re inclined to believe the cuts are more heavily weighted towards back-office operations. DOJ Overhang also Removed. In late March, CSII also reached an agreement in principle with the DoJ to settle claims underlying the ongoing investigation into sales practices." (4/1/2016)

Who owns Cardiovascular Systems stock?

Cardiovascular Systems' stock is owned by a number of of institutional and retail investors. Top institutional investors include Champlain Investment Partners LLC (5.07%), Frontier Capital Management Co. LLC (2.62%), State Street Corp (1.80%), Castleark Management LLC (1.10%), Thrivent Financial for Lutherans (0.89%) and Two Sigma Investments LP (0.70%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Brent G Blackey, Camber Capital Management Llc, David Martin, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley, Paul A Koehn, Robert J Thatcher and Scott R Ward.

Who sold Cardiovascular Systems stock? Who is selling Cardiovascular Systems stock?

Cardiovascular Systems' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Numeric Investors LLC, Renaissance Technologies LLC, Bogle Investment Management L P DE, Menta Capital LLC, GSA Capital Partners LLP, Two Sigma Investments LP and Frontier Capital Management Co. LLC. Company insiders that have sold Cardiovascular Systems stock in the last year include Alexander Rosenstein, Camber Capital Management Llc, Edward M Brown, Kevin J Kenny, Laura Gillund, Laurence L Betterley and Paul A Koehn.

Who bought Cardiovascular Systems stock? Who is buying Cardiovascular Systems stock?

Cardiovascular Systems' stock was bought by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Allianz Asset Management AG, Thrivent Financial for Lutherans, A.R.T. Advisors LLC, Marshall Wace LLP, State Street Corp, AQR Capital Management LLC and Teachers Retirement System of The State of Kentucky. Company insiders that have bought Cardiovascular Systems stock in the last two years include Brent G Blackey, Camber Capital Management Llc and Scott R Ward.

How do I buy Cardiovascular Systems stock?

Shares of Cardiovascular Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cardiovascular Systems stock cost?

One share of Cardiovascular Systems stock can currently be purchased for approximately $27.81.

Cardiovascular Systems (NASDAQ:CSII) Chart for Saturday, February, 25, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Earnings History Chart

Earnings by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Dividend History Chart

Dividend Payments by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Last Updated on 2/25/2017 by Staff